Lab
Elite Diagnostics, LLC
Elite Diagnostics, LLC was paid $1.09M by Medicaid between Jan 2018 and Dec 2024, across 44 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 26% of everything it billed.
33Billing provider infoELITE DIAGNOSTICS, LLC
CROWN POINT, IN 46307
CROWN POINT, IN 46307
33aNPI1467852350assigned 08/27/2014
33bProvider typeClinical Medical Laboratory
28Total paid$1.09M
24GClaims35,551
24DCodes billed44
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Indiana
Rank by total paid#14 of 66
Median peer was paid$53K
This provider vs. median21×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SINGH, KIRNJOT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,310 | $36K | |
| 2019 | 8,693 | $310K | |
| 2020 | 7,030 | $211K | |
| 2021 | 8,733 | $160K | |
| 2022 | 4,702 | $152K | |
| 2023 | 2,742 | $137K | |
| 2024incomplete | 2,341 | $86K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 26% | 9,167 | 5,438 | $287K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 19% | 5,354 | 3,187 | $208K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 18% | 2,070 | 1,327 | $197K |
| 82542 | 15% | 4,687 | 2,953 | $163K | |
| 80299 | 6.8% | 2,956 | 1,838 | $74K | |
| 83516 | 4.5% | 4,823 | 3,037 | $49K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.9% | 666 | 538 | $31K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.4% | 161 | 133 | $26K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 114 | 98 | $10K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 313 | 270 | $5K |
| 87486 | <1% | 135 | 117 | $4K | |
| 87581 | <1% | 135 | 117 | $4K |
32 more codes
| 87640 | <1% | 139 | $3K | |
| 80361 | <1% | 276 | $3K | |
| 80346 | <1% | 276 | $2K | |
| 80348 | <1% | 276 | $2K | |
| 80354 | <1% | 276 | $2K | |
| 80373 | <1% | 276 | $2K | |
| 80365 | <1% | 276 | $2K | |
| 80358 | <1% | 262 | $2K | |
| 80356 | <1% | 214 | $2K | |
| 80324 | <1% | 206 | $1K | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 73 | $1K |
| 80353 | <1% | 229 | $1K | |
| 80360 | <1% | 203 | $1K | |
| 80372 | <1% | 171 | $1K | |
| 80359 | <1% | 228 | $1K | |
| 80371 | <1% | 183 | $1K | |
| 83992 | <1% | 214 | $814.73 | |
| 80349 | <1% | 157 | $794.42 | |
| 80367 | <1% | 157 | $734.72 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 55 | $714.79 |
| 80321 | <1% | 157 | $600.14 | |
| 80333 | <1% | 58 | $347.84 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 24 | $336.59 |
| 80325 | <1% | 58 | $302.02 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 70 | $255.87 |
| 80370 | <1% | 58 | $198.58 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 43 | $192.19 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 136 | $191.55 |
| 80053 | Comprehensive metabolic panel | <1% | 44 | $145.53 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 45 | $121.50 |
| 80061 | Lipid panel | <1% | 32 | $88.98 |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 0% | 98 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSINGH, KIRNJOT (PRESIDENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.